+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Myelodysplastic Syndrome Market by Route of Administration (Oral, Parenteral), Drug Class (Alkylating Agents, Cytotoxic Antibiotics, Topoisomerase Inhibitors) - Forecast 2024-2030- Product Image
Global Myelodysplastic Syndrome Market by Route of Administration (Oral, Parenteral), Drug Class (Alkylating Agents, Cytotoxic Antibiotics, Topoisomerase Inhibitors) - Forecast 2024-2030- Product Image
Sale

Global Myelodysplastic Syndrome Market by Route of Administration (Oral, Parenteral), Drug Class (Alkylating Agents, Cytotoxic Antibiotics, Topoisomerase Inhibitors) - Forecast 2024-2030

  • PDF Icon

    Report

  • 188 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968770
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Myelodysplastic Syndrome Market size was estimated at USD 2.59 billion in 2023, USD 2.84 billion in 2024, and is expected to grow at a CAGR of 10.07% to reach USD 5.07 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Myelodysplastic Syndrome Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Myelodysplastic Syndrome Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Myelodysplastic Syndrome Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Bellicum Pharmaceuticals, BioLineRx Ltd., BluePoint Laboratories, Bristol-Myers Squibb Company, Celgene Corporation, Dr. Reddy's Laboratories, Eli Lilly and Company, Johnson & Johnson, MEI Pharma Inc., Novartis AG, Onconova Therapeutics, Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Myelodysplastic Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Route of Administration
    • Oral
    • Parenteral
  • Drug Class
    • Alkylating Agents
    • Cytotoxic Antibiotics
    • Topoisomerase Inhibitors
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Myelodysplastic Syndrome Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Myelodysplastic Syndrome Market?
  3. What are the technology trends and regulatory frameworks in the Myelodysplastic Syndrome Market?
  4. What is the market share of the leading vendors in the Myelodysplastic Syndrome Market?
  5. Which modes and strategic moves are suitable for entering the Myelodysplastic Syndrome Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Myelodysplastic Syndrome Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising geriatric population and increasing incidence of the syndrome
5.1.1.2. Improvements in healthcare services and advancements in stem cell transplantation and radiation therapy
5.1.1.3. Easy of availability and access to novel treatments
5.1.2. Restraints
5.1.2.1. High cost of novel therapeutics
5.1.3. Opportunities
5.1.3.1. Development of strong drug pipeline
5.1.3.2. Supportive government initiatives such as reimbursement policies
5.1.4. Challenges
5.1.4.1. Complexity and heterogeneity of novel treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Myelodysplastic Syndrome Market, by Route of Administration
6.1. Introduction
6.2. Oral
6.3. Parenteral
7. Myelodysplastic Syndrome Market, by Drug Class
7.1. Introduction
7.2. Alkylating Agents
7.3. Cytotoxic Antibiotics
7.4. Topoisomerase Inhibitors
8. Americas Myelodysplastic Syndrome Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Myelodysplastic Syndrome Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Myelodysplastic Syndrome Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AbbVie Inc.
12.1.2. Amgen Inc.
12.1.3. Bellicum Pharmaceuticals
12.1.4. BioLineRx Ltd.
12.1.5. BluePoint Laboratories
12.1.6. Bristol-Myers Squibb Company
12.1.7. Celgene Corporation
12.1.8. Dr. Reddy's Laboratories
12.1.9. Eli Lilly and Company
12.1.10. Johnson & Johnson
12.1.11. MEI Pharma Inc.
12.1.12. Novartis AG
12.1.13. Onconova Therapeutics, Inc.
12.1.14. Otsuka Pharmaceutical Co., Ltd.
12.1.15. Sun Pharmaceutical Industries Inc.
12.1.16. Takeda Pharmaceutical Company Limited
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. MYELODYSPLASTIC SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. MYELODYSPLASTIC SYNDROME MARKET SIZE, 2023 VS 2030
FIGURE 3. MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MYELODYSPLASTIC SYNDROME MARKET DYNAMICS
FIGURE 7. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 8. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. MYELODYSPLASTIC SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. MYELODYSPLASTIC SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. MYELODYSPLASTIC SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 6. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 9. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CYTOTOXIC ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 13. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 15. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 16. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 17. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 18. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 19. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 21. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 26. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. AUSTRALIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. AUSTRALIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. CHINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. CHINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. INDIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. INDIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. INDONESIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. INDONESIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. JAPAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. JAPAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. MALAYSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. MALAYSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. PHILIPPINES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. PHILIPPINES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. SINGAPORE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. SINGAPORE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. SOUTH KOREA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. SOUTH KOREA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. TAIWAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. TAIWAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. THAILAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. THAILAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. VIETNAM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. VIETNAM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. DENMARK MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. DENMARK MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. EGYPT MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. EGYPT MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. FINLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. FINLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. ISRAEL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. ISRAEL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. NETHERLANDS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. NETHERLANDS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. NIGERIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. NIGERIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. NORWAY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. NORWAY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. POLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. POLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. QATAR MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. QATAR MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. SAUDI ARABIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. SOUTH AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. SPAIN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. SPAIN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. SWEDEN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. SWEDEN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. SWITZERLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. SWITZERLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. TURKEY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. TURKEY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. UNITED ARAB EMIRATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. MYELODYSPLASTIC SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 99. MYELODYSPLASTIC SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
TABLE 100. MYELODYSPLASTIC SYNDROME MARKET LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Bellicum Pharmaceuticals
  • BioLineRx Ltd.
  • BluePoint Laboratories
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Johnson & Johnson
  • MEI Pharma Inc.
  • Novartis AG
  • Onconova Therapeutics, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Inc.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 2.84 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.07 Billion
Compound Annual Growth Rate10.0%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Myelodysplastic Syndromes Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type - Product Image

Myelodysplastic Syndromes Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type

  • Report
  • 90 Pages
  • Global
From
Global Myelodysplastic Syndrome Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis. - Product Image

Global Myelodysplastic Syndrome Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis.

  • Report
  • 164 Pages
  • Global
From
Myelodysplastic Syndrome Global Market Report 2024 - Product Image

Myelodysplastic Syndrome Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Myelodysplastic Syndrome - Pipeline Insight, 2024 - Product Image

Myelodysplastic Syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • 250 Pages
  • Global
From
Myelodysplastic Syndrome (MDS) Drugs Global Market Report 2024 - Product Image

Myelodysplastic Syndrome (MDS) Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From

About the Myelodysplastic Syndrome Drugs Market

Myelodysplastic Syndrome (MDS) is a type of cancer that affects the bone marrow and blood cells. It is a rare disorder that can lead to anemia, infections, and bleeding. Treatment for MDS includes chemotherapy, radiation therapy, and stem cell transplantation. Drugs used to treat MDS include hypomethylating agents, such as azacitidine and decitabine, and immunomodulatory agents, such as lenalidomide and pomalidomide. These drugs are used to reduce the risk of disease progression and improve the quality of life for patients. The Myelodysplastic Syndrome Drugs market is a part of the larger Oncology Drugs market. It is a rapidly growing market, driven by the increasing prevalence of MDS and the development of new drugs. The market is expected to continue to grow in the coming years, as new drugs are developed and approved for use. Some of the major companies in the Myelodysplastic Syndrome Drugs market include Celgene Corporation, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Merck & Co. Inc. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.